Your browser doesn't support javascript.
loading
Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors.
Sanborn, Rachel E; Pishvaian, Michael J; Callahan, Margaret K; Weise, Amy; Sikic, Branimir I; Rahma, Osama; Cho, Daniel C; Rizvi, Naiyer A; Sznol, Mario; Lutzky, Jose; Bauman, Julie E; Bitting, Rhonda L; Starodub, Alexander; Jimeno, Antonio; Reardon, David A; Kaley, Thomas; Iwamoto, Fabio; Baehring, Joachim M; Subramaniam, Deepa S; Aragon-Ching, Jeanny B; Hawthorne, Thomas R; Rawls, Tracey; Yellin, Michael; Keler, Tibor.
Afiliação
  • Sanborn RE; Providence Cancer Institute, Earle A. Chiles Research Institute, Portland, Oregon, USA Rachel.sanborn@providence.org.
  • Pishvaian MJ; Department of Oncology, Georgetown-Lombardi Comprehensive Cancer Center, Washington, District of Columbia, USA.
  • Callahan MK; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Weise A; Karmanos Cancer Institute, Detroit, Michigan, USA.
  • Sikic BI; Clinical and Translational Research Unit, Stanford Cancer Institute, Stanford, California, USA.
  • Rahma O; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA.
  • Cho DC; Perlmutter Cancer Center, NYU Langone Medical Center, New York, New York, USA.
  • Rizvi NA; Division of Hematology/Oncology, Columbia University Medical Center, New York, New York, USA.
  • Sznol M; Smilow Cancer Hospital, New Haven, Connecticut, USA.
  • Lutzky J; Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, USA.
  • Bauman JE; University of Arizona Cancer Center, Tuscon, Arizona, USA.
  • Bitting RL; Wake Forest Baptist Health, Winston-Salem, North Carolina, USA.
  • Starodub A; Parkview Research Center, Fort Wayne, Indiana, USA.
  • Jimeno A; Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
  • Reardon DA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Kaley T; Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Iwamoto F; Department of Neurology, Columbia Presbyterian Medical Center, New York, New York, USA.
  • Baehring JM; Department of Neurosurgery, Yale New Haven Health Smilow Cancer Hospital, New Haven, Connecticut, USA.
  • Subramaniam DS; Department of Oncology, Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia, USA.
  • Aragon-Ching JB; Inova Schar Cancer Institute, Fairfax, Virginia, USA.
  • Hawthorne TR; Celldex Therapeutics Inc New Haven, New Haven, Connecticut, USA.
  • Rawls T; Celldex Therapeutics Inc, Hampton, New Jersey, USA.
  • Yellin M; Celldex Therapeutics Inc, Hampton, New Jersey, USA.
  • Keler T; R & D, Celldex Therapeutics Inc, Hampton, New Jersey, USA.
J Immunother Cancer ; 10(8)2022 08.
Article em En | MEDLINE | ID: mdl-35940825
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Carcinoma de Células Renais / Neoplasias Renais Limite: Female / Humans Idioma: En Revista: J Immunother Cancer Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Carcinoma de Células Renais / Neoplasias Renais Limite: Female / Humans Idioma: En Revista: J Immunother Cancer Ano de publicação: 2022 Tipo de documento: Article